

Plataforma de  
telemedicina altamente  
lucrativa e de alto  
crescimento que atende  
a necessidade de



**MERGERSCORP**

## Plataforma de telemedicina altamente lucrativa e de alto crescimento que atende ao mercado alemão de cannabis medicinal

Oportunidade única de adquirir uma plataforma de telemedicina e prescrição digital totalmente remota, em rápida expansão e em conformidade com o GDPR, operando sob a estrutura transfronteiriça da UE. A empresa conecta mais de 20.000 pacientes a médicos e farmácias licenciados na Alemanha

Licença(s) detida(s)

Opera sob a estrutura de telemedicina transfronteiriça da UE (médicos licenciados na Alemanha e na Polônia). Plataforma em conformidade com o GDPR. Não é necessária nenhuma licença de manuseio direto de cannabis.

Detalhes da listagem

- A empresa sediada no Chipre opera uma plataforma de telemedicina totalmente digital, permitindo consultas remotas e prescrições digitais
- Lançada em 2024, a plataforma atendeu a aproximadamente 20.000 pacientes e processou mais de 6.500 prescrições por mês
- Concentrou-se na otimização profunda do processo para garantir a escalabilidade antes de lançar campanhas de marketing direcionadas, incluindo publicidade no Facebook e marketing de afiliados, e continua a implementar novos recursos para aprimorar a experiência do usuário
- Negócio lucrativo com margens superiores a 60%, uma taxa de execução de receita atual de aproximadamente 140.000 euros por mês e uma previsão de 1,5 milhão de euros até o final do ano, refletindo um crescimento anual de aproximadamente 20%.
- A receita é gerada por meio de agendamentos de consultas de pacientes, serviços de marketing para farmácias, parcerias com os principais produtores e ofertas de produtos de marca branca.
- Opera de forma eficiente com cerca de 12 funcionários/freelancers, aproveitando especialistas freelancers de front-end e back-end
- Os fluxos de trabalho automatizados reduzem o tempo de consulta médica em 90%, e a plataforma oferece suporte à funcionalidade de marca branca para uma rápida expansão B2B

GROSS REVENUE

\$ 1,680,000

EBITDA

\$ 1,008,000

BUSINESS TYPE

Empresas do setor de saúde

COUNTRY

Chipre

BUSINESS ID

L#20261003

- O crescimento anual projetado de 15 a 20% é impulsionado pela crescente demanda dos pacientes e pela recente liberalização do mercado alemão de cannabis
- Você está buscando a venda completa e inclui o negócio em andamento, a propriedade intelectual, a marca, o banco de dados de pacientes e a base de código do software

*The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction*

*The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.*

*By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.*

*This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.*

*The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.*

*All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.*

## MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

**MERGERSCORP**

[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)